^
Association details:
| Biomarker: | RAS wild-type + BRAF wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Excerpt:
...Overall Survival`Percentage of Participants With an Objective Response`Duration of Response`Time to Disease Progression`Time to Initial Objective Response`Resection Rate`Progression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS)`Progression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)`Overall Survival in Participants With Wild-type RAS`Overall Survival in Participants With Wild-type RAS / BRAF`Percentage of Participants With an Objective Response for Participants With Wild-type RAS`Percentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF`Number of Participants With Adverse Events (AEs)...
Trial ID:
Source:
Title:
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
Excerpt:
...Histologically proven diagnosis of colorectal cancer with wildtype RAS and BRAF status in certified laboratories; 3....
Trial ID:
Less C2 evidence
Source:
Title:
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV
Published date:
10/19/2023
Excerpt:
CONTRADICTING EVIDENCE: In the multivariable models, the impact of hyperselection on PFS and OS was confirmed. Lower ORR was observed with 5-FU/LV/panitumumab in GA (40% versus 62%), but not in HS (70% versus 72%)….Molecular hyperselection and comprehensive genomic profiling have a potential usefulness in elderly patients with RAS/BRAF wild-type, pMMR/MSS mCRC, eligible for upfront EGFR inhibition.
Secondary therapy:
5-fluorouracil + leucovorin calcium; FOLFOX
DOI:
10.1016/j.ejca.2023.113396
Source:
Title:
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation
Published date:
08/03/2023
Excerpt:
At a median follow-up of 50.0 months (IQR, 45.6-56.4), median PFS was 9.6 and 9.0 months for arm A and B, respectively (P < .001 in each arm). Overall response rate was 69% and 52%, whereas median overall survival was 23.5 and 22.0 months in arm A and B, respectively....Both mFOLFOX and 5-FU + LV + PAN are reasonable options as initial therapy of elderly patients with RAS/BRAF wild-type mCRC. 5-FU + LV + PAN is associated with a better safety profile.
Secondary therapy:
5-fluorouracil + leucovorin calcium
DOI:
10.1200/JCO.23.00506
Trial ID:
Source:
Title:
Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial
Published date:
06/30/2023
Excerpt:
Sixty-two patients with refractory RAS WT mCRC were randomly assigned to receive, as third-line therapy, trifluridine/tipiracil alone (arm A) or in combination with panitumumab (arm B)….Median PFS was 4.1 months (95% CI 1.44-6.83) for 17 patients treated with anti-EGFR rechallenge as compared to 3.0 months (95% CI 1.61-4.31) for seven patients that received other therapies (HR: 0.29, 95% CI 0.10-0.85, P = .024)....As expected, the benefit was observed only in the 13 patients with RAS/BRAF wt ctDNA with a mPFS of 5.4 months (2.8-8.0) and a mOS of 15.6 months...With the limit of a small phase 2 study, the results of the VELO trial indicate the key role of anti-EGFR rechallenge therapies in the continuum of care of refractory patients with pretreatment plasma RAS/BRAF WT ctDNA tumors.
Secondary therapy:
trifluridine/tipiracil
DOI:
10.1002/ijc.34632
Trial ID:
Source:
Title:
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
Published date:
05/18/2023
Excerpt:
Pretreatment plasma RAS/BRAF WT ctDNA identified patients obtaining prolonged clinical benefit with panitumumab plus trifluridine-tipiracil compared with trifluridine-tipiracil, with PFS rates at 6 months of 38.5% vs 13.0% and at 12 months of 15.4% vs 0%....In this RCT, third-line treatment with the anti-EGFR monoclonal antibody panitumumab plus the standard-of-care trifluridine-tipiracil resulted in improved PFS compared with treatment with trifluridine-tipiracil alone among patients with refractory RAS WT MCRC.
Secondary therapy:
trifluridine/tipiracil
DOI:
10.1001/jamaoncol.2023.0655
Trial ID:
